Category: Science

Categories
Business Economics Healthcare Lifestyle Perks Regulations & Security Science Travel & Leisure

Johnson & Johnson announces launch of Kenvue Inc. IPO roadshow

NEW BRUNSWICK, N.J. — (BUSINESS WIRE) — Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. “(Kenvue),” a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering “(IPO)” of 151,204,000 shares of its common stock.

 

Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol “KVUE.”

 

After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue’s common stock, representing 91.9% of the total outstanding shares of Kenvue’s common stock (or 90.8% if the underwriters exercise in full their over-allotment option).

 

Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the IPO. Citigroup, Deutsche Bank Securities, BNP Paribas, HSBC, RBC Capital Markets and UBS Investment Bank are acting as book-running managers for the IPO and BBVA, ING, IMI – Intesa Sanpaolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., Inc., R. Seelaus & Co., LLC and Siebert Williams Shank are acting as co-managers for the IPO.

 

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The IPO will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or by emailing: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by emailing: prospectus-eq_fi@jpmchase.com; or BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255, telephone: 1-800-294-1322, or by emailing: dg.prospectus_requests@bofa.com.

 

This press release is neither an offer to sell nor a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

 

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

 

Cautions Concerning Forward-Looking Statements

This release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: the timing and details of the IPO, the number of shares to be offered in the IPO, the expected price at which such shares will be offered, the grant of the over-allotment option and whether the underwriters will exercise such option, the number of shares to be held by Johnson & Johnson following the IPO and the expectations relating to the listing of Kenvue’s common stock on the New York Stock Exchange. Readers are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: Johnson & Johnson’s ability to satisfy the necessary conditions to consummate the separation of Kenvue on a timely basis or at all; Johnson & Johnson’s ability to successfully separate Kenvue and realize the anticipated benefits from the separation; Kenvue’s ability to succeed as a standalone publicly traded company; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including unexpected clinical trial results, additional analysis of existing clinical data, uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; the ability of Johnson & Johnson to successfully execute strategic plans, including restructuring plans; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws, global health care reforms and import/export and trade laws; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the section captioned “Cautionary Note Regarding Forward-Looking Statements”, and in Johnson & Johnson’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this press release speaks only as of the date of this press release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Contacts

Investor Relations:
Jessica Moore (Johnson & Johnson)

investor-relations@its.jnj.com

Tina Romani (Kenvue)

Kenvue_IR@kenvue.com

Categories
Healthcare International & World Lifestyle Science

Quizartinib NDA review for patients with newly diagnosed FLT3-ITD positive AML extended by FDA

TOKYO & BASKING RIDGE, N.J. — (BUSINESS WIRE) — Daiichi Sankyo (TSE: 4568) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) of quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive.

 

The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by three months to July 24, 2023 to allow additional time to review requested updates to the proposed Risk Evaluation and Mitigation Strategies (REMS) included in this application. No additional efficacy or safety data has been requested.

 

“We are continuing to work with the FDA to facilitate completion of their review of the quizartinib new drug application in order to bring this important medicine to patients as soon as possible,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo. “Quizartinib was shown to improve overall survival when added to standard chemotherapy and continued as monotherapy and has potential to change the standard of care for patients with newly diagnosed FLT3-ITD positive AML.”

 

The NDA is based on results from the QuANTUM-First trial, which demonstrated that quizartinib combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and continued as monotherapy following consolidation, resulted in a statistically significant and clinically meaningful improvement in overall survival in adult patients with newly diagnosed FLT3-ITD positive AML compared to chemotherapy alone. The results of QuANTUM-First were presented at the 2022 European Hematology Association (EHA) Congress.1

 

The safety of quizartinib combined with intensive chemotherapy and as continuation monotherapy in QuANTUM-First was generally manageable with no new safety signals observed. The incidence of grade ≥3 QT prolongation events was low, with uncommon ventricular arrythmia events. Overall, the risk of QT prolongation was manageable with ECG monitoring, quizartinib dose modification and correction/elimination of additional risk factors.

 

About QuANTUM-First

QuANTUM-First is a randomized, double-blind, placebo-controlled global phase 3 study evaluating quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, in adult patients aged 18-75 with newly diagnosed FLT3-ITD positive AML. Patients were randomized 1:1 into two treatment groups to receive quizartinib or placebo combined with anthracycline- and cytarabine-based regimens. Eligible patients, including those who underwent hematopoietic stem cell transplant (HSCT), continued with quizartinib or placebo for up to 36 cycles.

 

The primary study endpoint was overall survival. Secondary endpoints include event-free survival, post-induction rates of complete remission (CR) and composite complete remission (CRc), and the percentage of patients who achieve CR or CRc with FLT3-ITD minimal residual disease negativity. Safety and pharmacokinetics, along with exploratory efficacy and biomarker endpoints, also were evaluated. QuANTUM-First enrolled 539 patients at 193 study sites across Asia, Europe, North America, Oceania and South America. For more information, visit ClinicalTrials.gov.

 

About FLT3-ITD Positive Acute Myeloid Leukemia

More than 474,500 new cases of leukemia were reported globally in 2020 with more than 311,500 deaths.2 AML accounts for 23.1% of total leukemia cases worldwide and is most common in adults.3,4 In the U.S., an estimated 20,380 new cases of AML will be diagnosed in 2023 with the five-year survival rate reported at 30.5%.4,5

 

A number of gene mutations have been identified in AML, and FLT3 (FMS-like tyrosine kinase 3) mutations are the most common, observed in up to 37% of all newly diagnosed patients.6,7 Approximately 80% of FLT3 mutations in AML are FLT3-ITD (internal tandem duplications), an oncogenic driver mutation that presents with a high leukemic burden.7,6 Patients with FLT3-ITD positive AML tend to have a particularly unfavorable prognosis including increased risk of relapse and shorter overall survival.6 The five-year survival rate for patients with FLT3-ITD positive AML has been reported at approximately 20%.8

 

The conventional treatment for fit patients with newly diagnosed AML is intensive induction and consolidation chemotherapy, with or without targeted therapy, and HSCT for eligible patients.9

 

About Quizartinib

Quizartinib is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.6

 

Regulatory applications for quizartinib in newly diagnosed FLT3-ITD positive AML are currently under review in Europe, Japan and the U.S. based on the results of the QuANTUM-First trial. The FDA has granted Priority Review and Fast Track Designation to quizartinib for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy. Orphan Drug Designation has been granted to quizartinib for the treatment of AML in Europe, Japan and the U.S.

 

Quizartinib is approved for use in Japan for the treatment of adult patients with relapsed/refractory AML that is FLT3-ITD positive, as detected by an approved test. Quizartinib is an investigational medicine in all countries outside of Japan. The quizartinib clinical development program includes a phase 1/2 trial in pediatric and young adult patients with relapsed/refractory FLT3-ITD positive AML in Europe and North America and several phase 1/2 combination studies as part of a strategic collaboration with The University of Texas MD Anderson Cancer Center.

 

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

 

References

1 Erba H et al. EHA Library. Presidential Symposium. 06/11/22; 356965; S100

2 Global Cancer Observatory. Population Fact Sheet: World. Updated March 2021.

3 Dong Y et al. Exp Hematol Oncol. 2020;9:14.

4 American Cancer Society: Key Statistics for Acute Myeloid Leukemia. Updated January 2023.

5 National Cancer Institute SEER Program. Cancer Stat Facts: Acute Myeloid Leukemia
6 Daver N et al. Leukemia. (2019) 33:299–312.

7 Patel JP et al N Engl J Med. 2012 Mar 22;366(12):1079-89.

8 Frohling et al. Blood. (2002) 100 (13): 4372–4380.

9 Daver et al. Blood Cancer J. 2020;10(10):107.

Contacts

Media Contacts:

Global/US:
Jennifer Brennan

Daiichi Sankyo, Inc.

jbrennan2@dsi.com
+1 908 900 3183 (mobile)

Japan:
Koji Ogiwara

Daiichi Sankyo Co., Ltd.

ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp

Categories
Business Lifestyle Regulations & Security Science Technology

Engineering Solutions and Meadowgate Technologies combine to create hybrid IT leader serving national security sector

Maryland companies join forces to deliver full-service hybrid technology capabilities

 

ANNAPOLIS JUNCTION, Md. — (BUSINESS WIRE) — Maryland companies Engineering Solutions LLC (ESi) and Meadowgate Technologies LLC today announced they are combining to create a market leader in hybrid technology solutions and professional services for the national security community.

 

The new company will be led by Meadowgate CEO Tom Lash, a former national security leader at AWS’ Federal Division, who joined Meadowgate earlier this year. He is spearheading a strategy to build a business aligned with growing customer demand for the unique operational agility and security that advanced hybrid solutions can deliver.

“This combination is a pivotal move in our hybrid technology strategy,” said Lash. “ESi’s technical expertise, specialist professional services, and profound understanding of the mission objectives of their customers blend exceptionally well with the product knowledge and systems integration expertise of the Meadowgate team. We are particularly excited at the potential this creates for collaboration on new hybrid product and service innovations through our Integration Lab, working alongside our customers and partners in industry. We can’t wait to get started.”

 

By harnessing complementary skills, experience and capabilities, ESi and Meadowgate are creating a full-service hybrid solutions client experience ranging from technology evaluation to systems integration and through-life services support. The new company will offer technology consulting, product procurement and integration, solution development, systems engineering, enterprise resiliency and hybrid workload development, migration, and management.

  • ESi, established in 1998 and based in Hanover, Maryland, has grown its professional services team to over 100 cleared, highly educated and certified specialists skilled in software and system engineering, information technology management, enterprise resiliency, and SIGINT operations and analysis for the intelligence community. The company is dedicated to supporting the national security mission, with a longstanding reputation for delivering technical and execution excellence for its valued customers. Building on ESi’s success as a prime contractor, the firm brings a significant pipeline of new business to the combined organization to drive future growth.
  • Meadowgate is an award-winning business that’s been delivering trusted computing products and services to the federal government since 2006. It has a successful track record of enabling complex federal missions by providing high-performance computing solutions. The company’s growth strategy centers on aligning offerings and talent with the national security community’s growing demand for scalable systems architectures and capabilities that enable seamless movement of data and workloads within hybrid environments. Meadowgate’s Integration Lab will be the R&D hub for the combined company, where the teams come together to apply their collective mission and technical understanding to design and develop new hybrid solutions that improve mission outcomes.

 

Ray Gomes, founder and CEO of ESi, who has announced his intention to retire, will remain with the combined business as a strategic adviser. ESi’s executive team, including Chief Operations Officer Amy Steinberg, Vice President of Programs Eddie Harless and Executive Vice President of Corporate Services David Thompson, will join the leadership team of the combined company.

 

“I am delighted that the team at ESi will be a cornerstone of this exciting growth strategy,” said Gomes.

 

“As I step aside as ESi CEO, it has been my priority to ensure that the company has the best possible opportunity to build on its success for the long term within an employee-focused culture. Coming together with Meadowgate to create a business at the nexus of technology and the mission opens new paths to growth and strengthens our value to customers, presenting more opportunities for the team to shine. I look forward to seeing the company thrive at the forefront of building the hybrid solutions of the future.”

 

ESi and Meadowgate will continue to be customer facing under their respective brand names. At the same time, the combined company leadership, drawn from the existing ESi and Meadowgate executive teams, will be working together to begin the formal integration process and determine the future brand for the new company.

 

KippsDeSanto & Co. acted as the exclusive financial adviser to ESi on this combination.

 

About Engineering Solutions

Engineering Solutions LLC (ESi) supports customers that safeguard our country. ESi is dedicated to serving America’s national security mission by providing technical and execution excellence to intelligence community customers in the areas of software and systems engineering, IT management, enterprise resiliency, and SIGINT operations and analysis. Achieving success for critical missions since 1998, ESi is based in Hanover, Maryland. www.enginsol.com

 

About Meadowgate Technologies

Meadowgate Technologies LLC delivers advanced, trusted IT solutions and products to national security customers and partners. The company specializes in systems engineering, consulting and product procurement to meet the unique needs of each federal agency or industry customer. Established in 2006, Meadowgate is based in Annapolis Junction, Maryland, with offices in Trenton, New Jersey. www.meadowgate.us

Contacts

Kristina Messner

kristina@messnermediagroup.com
703-716-3181

Categories
Business Education Lifestyle Programs & Events Science Technology

Ten schools named National Finalists in Samsung’s Solve for Tomorrow STEM competition

Students’ Creative Solutions to Community Issues Earn Each Finalist School $50,000 in Samsung Technology & Supplies

 

RIDGEFIELD PARK, N.J. — (BUSINESS WIRE) — Samsung Electronics America today named 10 National Finalist schools from among this year’s 50 State Winners in the 13th annual Samsung Solve for Tomorrow competition. Each National Finalist will receive a prize package of $50,000 in Samsung technology and supplies.

 

Solve for Tomorrow challenges public school students in grades 6-12 to use science, technology, engineering, and math (STEM) skills to create positive change in their communities. The students behind the Finalists’ innovative projects, which address reducing food waste and insecurity, helping unhoused refugees, subway safety, accessibility, and water quality, will pitch their ideas on May 15, 2023 to a panel of judges at a live event in Washington, D.C. Three schools will then be chosen as National Winners and receive $100,000 in prizes.

 

“After three years of COVID disruptions that impacted students and educators alike, it’s been incredibly rewarding to see our Samsung Solve for Tomorrow competition play a part in re-energizing the ingenuity and creativity that had been hobbled by remote learning and isolation for STEM students,” said Ann Woo, Senior Director, Corporate Citizenship, Samsung Electronics America. “The cooperative, hands-on, problem-solving focus of the Solve for Tomorrow challenge provided a spark for students looking to channel their energies to tackle issues that they see in their communities. These National Finalist students, teachers, and schools exhibit what we call STEMpathy – the use of STEM to help fix the issues they see affecting their friends and neighbors, people they EMPATHIZE with.”

 

All 50 State Winners in the prior round of the Solve for Tomorrow competition produced a three-minute video describing their project, the local community issue it addresses, and their proposed STEM-based solution. The National Finalists were selected based on their videos. Between now and May 15, 2023, the general public can vote online for one Community Choice Winner from among the pool of 10 National Finalists, who will win an additional $10,000 prize package. To choose your favorite Solve for Tomorrow Community Choice STEM solution, check out the Finalists’ videos, which can be viewed here:

 

SCHOOL

CITY/STATE

COMMUNITY ISSUE & STEM SOLUTION

Brandywine High School

Wilmington, DE

AACU Switch – AACU Switch eliminates cost barriers by creating an affordable alternative to assistive tech devices for people with independent living disabilities, costing a fraction of the market standard.

Strawberry Crest High School

Dover, FL

Human Health Band – The Human Health Band is a wearable sensor with an app that allows coaches to monitor athlete’s body temperatures and prevent heat related death.

Richmond Hill Middle School

Richmond, GA

Safe Sleep – Safe Sleep’s purpose is to detect sudden increases in heart rate during a PTSD nightmare. This will trigger a companion app to play breathing exercises.

Bloomington High School South

Bloomington, IN

Temp Mural – Temp Mural reduces the impact of global warming by engineering mural art using highly reflective, climate-positive barium sulfate paint.

Merrimack Valley High School

Penacook, NH

Shelby – Shelby combats rising phosphorus levels in bodies of water with a turtle-shaped battery-powered robot with mechanical and chemical filters.

Santa Teresa High School

Santa Teresa, NM

The Living Lumbre – The Living Lumbre is a smart solar-powered heated mat in response to the large flow of refugees who have ended up homeless in our community.

Doral Academy of Northern Nevada

Reno, NV

Food Waste App – The Food Waste App diminishes food waste/insecurity and reduce greenhouse gas emissions by connecting food producers with people to convert produce into meals.

Liberty Avenue Middle School

Brooklyn, NY

Subsave – Subsave is an alert sensor within an app that will work along with the MTA help points to support commuters by discreetly reporting either a 911 emergency to police or a mental health emergency to mobile mental health responders.

Porter High School (Autumn D.)

Porter, TX

HiveHub – HiveHub is a state-of-the-art beehive monitoring system capable of recording the hive traffic, climate, and activity, all the while giving live feedback through the user-friendly app.

Greenbrier East High School

Lewisburg, WV

Mining Sensor – Mining Sensor assists with and expedites locating and rescuing lost cavers by sending a digital signal from the cavers to the surface.

 

“It was a difficult process for the judges to winnow down the full set of fifty State Winners to our ten National Finalists,” added Woo. “All the Samsung Solve for Tomorrow teams showed tremendous determination to help their communities. They worked hard on their projects and video presentations. And we believe that all State Winner teams deserve to be seen and celebrated as the talented and compassionate STEM heroes they truly are.”

 

Up next in the Samsung Solve for Tomorrow competition:

  • The 10 National Finalists will head to a live Pitch Event on May 15 in Washington, D.C. Judges will then select three National Winners, who will each receive $100,000 in prizes.
  • One of the 50 State Winners will be honored as our Sustainability Innovation Award Winner, receiving an added $50,000 prize package of eco-conscious classroom technology.
  • Of the 10 National Finalists, one will be named Community Choice Winner through online public voting, receiving an additional $10,000 in Samsung technology. To participate, simply view the student-created videos on the Samsung Solve for Tomorrow website and cast your vote. Voting is permitted once a day until 11:59 p.m. EDT on May 15, 2023.
  • Samsung employees will name one team this year’s Employee Choice Winner. That honor earns the winning school an added $10,000 of Samsung technology on top of their national winnings.

 

Across all award categories in Solve for Tomorrow, more than $2 million* in Samsung technology and classroom supplies will be distributed in the 2022-23 competition.

 

As part of Samsung’s guiding vision of ‘Together for Tomorrow! Enabling People’, Solve for Tomorrow launched in 2010 to encourage innovative thinking, creative problem-solving, and teamwork to address the most pressing issues impacting society. To date, Samsung Solve for Tomorrow has awarded $24 million in classroom technology and materials to 2,791 public schools in the United States.

 

To learn more about the national STEM competition, please visit www.samsung.com/solve or follow us on Instagram or Facebook.

*$2 million prize is based on an estimated retail value.

Contacts

Media: Nancy Zakhary, SamsungSFT@relev8.co

Categories
Culture Environment Lifestyle Local News Programs & Events Science

Rutgers Master Gardeners of Mercer to hold annual Plant Expo and Garden Market

It’s about Blooming Time!

 

Rutgers Master Gardeners of Mercer County’s annual Spring Plant Expo and Garden Market will be Saturday, May 6 from 9 a.m. to 2 p.m. at the Mercer Educational Gardens, 431A Federal City Road, Hopewell Township.

PHOTO: The Mercer Master Gardeners are planning their annual Plant Expo and Garden Market, which will be held on Saturday, May 6, 9 a.m. to 2 p.m., rain or shine, at the Mercer Educational Gardens on the grounds of the Mercer County Stables in Hopewell Township. Pictured, from left, are Expo co-chairs Carol Bencivengo of Hamilton, Stephanie Foy of West Windsor, Ann Mann of Princeton, Harri Nowrey of Hamilton, and Susan Maley of Columbus.

 

One of the most celebrated events of the year, the Expo will be on the grounds of Mercer County Stables. The event is held rain or shine! Free parking is on site.

 

This year’s Expo will feature the much sought after home-grown perennials, trees, and shrubs from the gardens of Rutgers Master Gardeners and a garden market with select vendors.

 

The vendors are Steven Kristoph Nursery, Millstone Township; Shannon’s Nursery, Doylestown, Pa.; Byrne Farm Market, Wrightstown; and Chickadee Creek Farm, Pennington. Additionally, the Master Gardeners are excited to announce the addition of a new vendor, Moon Shot Farm of East Windsor.

 

Meet these select growers and purchase a wide variety of native plants, woody ornamentals, perennials, annuals, tomatoes, veggies, herbs and cut flowers.

 

Plan to arrive early for the best selection! Rutgers Master Gardeners will be on hand to help you choose the right plant for the right place and will answer all your questions.

 

Visit www.mgofmc.org for more information on vendors, a home-grown plant inventory, plant resources, and other sale details.

 

CONTACT: Meredith Melendez  (609) 989-6830; melendez@njaes.rutgers.edu

The Rutgers Master Gardeners of Mercer County is a volunteer educational outreach program of Rutgers Cooperative Extension. Master Gardeners participate in many volunteer programs throughout the County. For home gardening, plant, turf, or insect questions, you can visit our Helpline office at Rutgers Cooperative Extension of Mercer County, Monday through Friday, and speak with a Rutgers Master Gardener volunteer. You can also call us, (609) 989-6853, or send us an email AsktheMGs@mercercounty.org. Visit our website at www.mgofmc.org for Helpline hours and more information.

Categories
Business Lifestyle Regulations & Security Science Technology

Corvus and Core Specialty to deliver expansion of AI-powered Excess Tech E&O and Cyber product

Core Specialty’s first in the Cyber and Tech E&O market

 

BOSTON — (BUSINESS WIRE) — Corvus Insurance, the leading cyber underwriter, powered by a proprietary AI-driven cyber risk platform, announced today the launch of a new program with Core Specialty to support the expansion of the Excess Tech E&O and Cyber product with additional capacity. This is Core Specialty’s first offering in the Cyber and Tech E&O market and also marks the latest example of Corvus’s commitment to building out its key lines of business.

This program provides up to $5M in coverage for companies with revenues up to $500MM. The program will be written on Core Specialty’s paper and will include Tech E&O coverage, as well as a full suite of Cyber coverages, on an excess basis. The program is supported by a leading panel of reinsurers as well as risk taken through Corvus’s captive, Corvus Reinsurance Company. Corvus’s in-house team will have full management of the policies – from underwriting to claims handling.

 

This latest announcement follows Corvus’s recent launch of Corvus Risk Navigator™, which enables underwriters to provide predictive, data-driven insights, superior risk selection and accelerated decision-making, and IT security recommendations. Brokers who are looking to secure Tech E&O coverage stand to gain tremendous benefits from Corvus’s data-driven method of underwriting. Brokers can leverage Corvus’s policyholder benefits such as risk management tools and personalized vulnerability alerting on both primary and excess Tech E&O placements.

 

“We are thrilled to have the validation of Core Specialty, a well-known leader in specialty insurance. Both Core Specialty and Corvus put underwriting excellence and results first, so we view ourselves as natural partners,” said Corvus CEO Madhu Tadikonda. “Core Specialty’s commitment is a testament to Corvus’s proven track record combining growth with industry-leading loss ratios. The Corvus formula works — arming the strongest underwriters with best-in-class data and technology means accurate risk selection, better broker experience, and superior underwriting outcomes. We have the best team in the industry and are excited to expand our realm of possibilities with broker partners, thanks to this partnership, including the roll-out of excess capacity.”

 

“We chose Corvus for our first foray into Cyber and Tech E&O because of its unique and modern approach to combining skilled underwriting with data-driven technology,” said Jeff Consolino, President and CEO of Core Specialty. “We are impressed by Corvus’s talented team of cybersecurity underwriters, technology, and data science professionals, and look forward to working together to support a full spectrum of Tech E&O business — starting with this excess coverage. The Tech E&O and Cyber product will complement Core Specialty’s Commercial Errors & Omissions Liability products and services for small and medium sized businesses and professionals where we deliver a wide range of protection to help cover loss and defense costs that come from claims of professional negligence, error, or omission.”

 

About Corvus Insurance

Corvus Insurance is building a safer world through insurance products and digital tools that reduce risk, increase transparency, and improve resilience for policyholders and program partners. Our market-leading specialty insurance products are enabled by advanced data science and include Smart Cyber Insurance® and Smart Tech E+O™. Our digital platforms and tools enable efficient quoting and binding and proactive risk mitigation. Corvus Insurance offers insurance products in the U.S., Middle East, Europe, Canada, and Australia. Current insurance program partners include Crum & Forster, Hudson Insurance Group, certain underwriters at Lloyd’s of London, R&Q Accredited, SiriusPoint, and The Travelers Companies, Inc. Corvus Insurance, Corvus London Markets, and Corvus Germany are the marketing names used to refer to Corvus Insurance Agency, LLC; Corvus Agency Limited; and Corvus Underwriting GmbH. All entities are subsidiaries of Corvus Insurance Holdings, Inc. Corvus Insurance was founded in 2017 and is headquartered in Boston, Massachusetts with offices across the U.S., in the UK, and Germany. For more information, visit corvusinsurance.com.

 

About Core Specialty

Core Specialty offers a diversified range of property and casualty insurance products for small to midsized businesses. From its underwriting offices spanning the U.S., the Company focuses on niche markets, local distribution, and superior underwriting knowledge; offering traditional as well as innovative insurance solutions to meet the needs of its customers and brokers. Core Specialty is an insurance holding company operating through StarStone Specialty Insurance Company, a U.S. excess & surplus lines insurer, and StarStone National Insurance Company, Lancer Insurance Company, and Lancer Insurance Company of New Jersey, each of which is a U.S. admitted markets insurer. All Core Specialty Insurance entities are rated A- (Excellent); the StarStone companies are Financial Size Category XII and the Lancer entities are Financial Size Category of VII. For further information about Core Specialty, please visit www.corespecialty.com.

Contacts

Inkhouse PR, Jen Weber

corvus@inkhouse.com

Categories
Business Healthcare Lifestyle Science Special/Sponsored Content

Rocket Pharmaceuticals to participate in upcoming Investor Conferences

CRANBURY, N.J. — (BUSINESS WIRE) — Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Company management will participate in the 22nd Annual Needham Virtual Healthcare Conference and Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.

 

Participation details are as follows:

22nd Annual Needham Virtual Healthcare Conference

Fireside Chat Presentation

Date: April 18, 2023

Time: 8:45 a.m. ET

 

Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Fireside Chat Presentation

Date: April 25, 2023

Time: 9:00 a.m. ET

A webcast of both events will be available under “Events” in the Investors section of the Company’s website at https://ir.rocketpharma.com/.

 

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LV) based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. Rocket also has preclinical AAV-based gene therapy programs in PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated dilated cardiomyopathy (DCM). For more information about Rocket, please visit www.rocketpharma.com.

 

Rocket cautionary statement regarding forward-looking statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, Rocket’s plans for the advancement of its Danon Disease program, including its planned pivotal trial, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “design,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “will give,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, our ability to submit regulatory filings with the U.S. Food and Drug Administration (FDA) and to obtain and maintain FDA or other regulatory authority approval of our product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, our competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, our integration of an acquired business, which involves a number of risks, including the possibility that the integration process could result in the loss of key employees, the disruption of our ongoing business, or inconsistencies in standards, controls, procedures, or policies, our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire and any unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 28, 2023 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Media
Kevin Giordano

kgiordano@rocketpharma.com

Investors
Brooks Rahmer

investors@rocketpharma.com

Categories
Education Healthcare Lifestyle Local News Science

Leading NJ public health school announces new health and risk communication certificate

TCNJ’s Public Health department offers new all-online Health & Risk Communication certificate.

 

“Our department wants to arm public health and non-profit communities with the skills they need to succeed…”

— Slyvia Twersky, PhD, MPH, TCNJ Public Health Asst. Professor

 

EWING, N.J. – In March, a new report announced 2021 as a 58-year high for maternal mortality. The same study pointed out delayed preventive care during COVID and continued disparities in social determinants of health as key contributors.

 

As at-risk communities face mounting health challenges, the School of Nursing and Health Sciences (SNHS) at The College of New Jersey (TCNJ) is preparing students to help people pursue healthier lives with a new graduate certificate in health and risk communication.

 

Consisting of four courses, the new program will teach students how to develop, implement, and evaluate health communication plans — from research to program testing. Students will learn about health communication campaigns in community contexts, social media, digital health platforms and interactive video games.

 

TCNJ Public Health and Communication Studies professor, John C. Pollock, PhD, expands on the benefits of this new program, saying, “This innovative graduate certificate offers robust training in creating, implementing, and evaluating professional health communication campaigns. Taught by health communication scholars and professionals, certificate courses employ knowledge about message formation and communication to teach students how to alleviate suffering, reduce risky behavior, and promote health equity.”

 

Credits generated from this certificate can be applied to a Master’s in Public Health degree from TCNJ. TCNJ’s Public Health program ranks number two in New Jersey.

 

TCNJ Public Health Assistant Professor and Graduate Program Director, Sylvia Twersky, PhD, MPH, adds, “Our department wants to arm public health and non-profit communities with the skills they need to succeed and thrive in their jobs and create healthier communities. This certificate in health and risk communication helps us do that. As a completely online program, it can meet the needs of today’s busy professionals. It is also compatible with an MPH in Health Communication, so if a student wants to convert the certificate into a master’s degree, they have a clear path forward.”

 

The School of Nursing and Health Sciences’ Dean Carole Kenner explains, “This new health and risk communication certificate is an example of how our Public Health program empowers students to positively impact surrounding communities during and after their college experiences. Whether for a full Master’s degree or skills improvement, our diverse certificate offerings give anyone the opportunity to advance their knowledge and empower others.”

 

The School rebranded in 2022 to reflect its robust and diverse, cross-disciplinary health science curricula.

 

TCNJ’s School of Nursing and Health Sciences educates aspiring health professionals to become future leaders across the healthcare industry. Faculty work closely with local healthcare partners to provide students with applicative skills and foundational knowledge. The nationally acclaimed school is dedicated to preparing individuals—through programs in nursing, public health, exercise science and physical education teaching—for the many rewards of guiding people, communities, and populations toward improved health outcomes. The School is nationally recognized as a Healthy People 2030 Champion.

 

Contact Information:

Crothers Consulting | info@crothersconsulting.co | (800) 831-3840

Source: TCNJ School of Nursing and Health Sciences

Categories
Business Healthcare International & World Science

Stemmer Distribution optimizes communications infrastructure with Avaya – Delivering 50% cost savings and enhanced employee experiences

Largest Dental Product Distributor in France Harmonizes Communications Solutions with Avaya Cloud Office® by RingCentral

 

MORRISTOWN, N.J. — (BUSINESS WIRE) — Avaya, a global leader in solutions to enhance and simplify communications and collaboration, today announced Stemmer Distribution, the largest distributor of dental products in France, has successfully harmonized and modernized its communications infrastructure with the help of Avaya Cloud Office® by RingCentral. Stemmer Distribution sought a new, more modern communication solution that met all the needs of reachability and mobility, while rationalizing costs for the present and future.

Avaya partner, Artelcom, conducted a technical and functional audit of the entire existing communications infrastructure, identifying various strategies for the evolution of the communications solutions for the 250 employees spread over six business units in France. Stemmer Distribution chose the Avaya UCaaS solution, Avaya Cloud Office, which met the group’s specifications, providing an intuitive, easy-to-use solution that is perfect for their mobility needs.

 

“We had considered migrating to a hosted solution in a datacenter, but the feedback from our provider Artelcom convinced us of the reliability and flexibility of the Avaya Cloud Office public cloud solution,” explains Alexandre Sicard, Infrastructure Manager, Stemmer Distribution. “In just a few months, we migrated to an innovative and high-performance cloud solution. Avaya Cloud Office has allowed us to harmonize and modernize our communication infrastructure while providing a more intuitive and mobile-friendly solution for our employees. We have been able to reduce our telecom budget, delivering cost savings without compromising on performance. Avaya Cloud Office truly embodies innovation without disruption.”

 

Thanks to the Avaya Cloud Office solution, Stemmer Distribution has reduced its cost-per-user by 50%, while harmonizing the communications infrastructure to deliver a consistent experience for employees and customers. The solution also facilitates simplified management and administration for the IT Department, allowing them to focus on more strategic projects.

 

“Today’s businesses are evolving their processes and a cloud communications platform provides everything employees need to be effective communicators, all on a single device, from anywhere they may be,” said Tim Sherwood, GVP of Product and Offer Management, Avaya. “Avaya Cloud Office is one of the ultimate solutions for today’s businesses seeking seamless communication and collaboration, with enterprise grade voice, video, messaging, meetings, and conferencing capabilities. With Avaya Cloud Office, customers can have their entire workforce on a single system, enabling easy collaboration and efficient operations, whether in-office, remote, or mobile. By simplifying communication and delivering greater cost savings, Avaya Cloud Office is the perfect choice for businesses seeking a competitive edge in today’s fast-paced world.”

 

The success of the solution in France has opened the possibility of deploying the Avaya Cloud Office solution in other European organizations to modernize their businesses.

 

Additional Resources

 

About Avaya

Businesses are built by the experiences they provide, and every day millions of those experiences are delivered by Avaya. Avaya is shaping the future of customer experiences, with innovation and partnerships that deliver game-changing business benefits. Our communications solutions power immersive, personalized, and memorable customer experiences to help organizations achieve their strategic ambitions and desired outcomes. Together, we are committed to helping grow your business by delivering Experiences That Matter. Learn more at http://www.avaya.com.

 

About Stemmer Distribution

The Stemmer Distribution Group is the largest distributor of dental products in France.

It supplies all health professionals in the dental sector with consumables, laboratory products, equipment and equipment repair services. Founded in 1978 by Armand Stemmer, the company has experienced strong growth and has since established itself in 8 European markets: Portugal, Spain, Italy, United Kingdom, Belgium, Switzerland and the Netherlands. The Stemmer Group, headed by Vivian Stemmer (CEO), is organized around three Business Groups: Distribution, Innovation and Digital.

 

Cautionary Note Regarding Forward-Looking Statements

This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “our vision,” “plan,” “potential,” “preliminary,” “predict,” “should,” “will,” or “would” or the negative thereof or other variations thereof or comparable terminology. These forward-looking statements are subject to a number of factors and uncertainties that could cause the Company’s actual results to differ materially from those expressed in or contemplated by the forward-looking statements. Such factors include, but are not limited to, risks attendant to the bankruptcy process, including the Company’s ability to emerge successful from the Company’s voluntary cases under chapter 11 of the United States Bankruptcy Code, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021, subsequent quarterly reports on Form 10-Q filed with the SEC and other public statements made from time-to-time. These risks and uncertainties may cause the Company’s actual results, performance, liquidity or achievements to differ materially from any future results, performance, liquidity or achievements expressed or implied by these forward-looking statements. The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this report may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

 

All trademarks identified by ®, TM, or SM are registered marks, trademarks, and service marks, respectively, of Avaya Inc. All other trademarks are the property of their respective owners.

 

Source: Avaya Newsroom

Contacts

Alex Alias, Avaya

alalias@avaya.com

Categories
Education Environment Lifestyle Science Special/Sponsored Content

Rutgers info on Wild Plant Culture to restore edible and medicinal native plant communities